(AMRN) Amarin - Ratings and Ratios
Omega-3 Fatty Acid, Prescription Medicine, Cardiovascular Therapy
AMRN EPS (Earnings per Share)
AMRN Revenue
Description: AMRN Amarin
Amarin Corporation PLC is a pharmaceutical company specializing in the development and commercialization of therapeutics for cardiovascular diseases. The companys primary product, VASCEPA, is a prescription-only omega-3 fatty acid used to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Amarin sells VASCEPA through wholesalers, regional wholesalers, and specialty pharmacy providers, and has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize related drug products.
To further analyze Amarins performance, we can examine key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses. Given the companys focus on VASCEPA, its essential to track the products sales growth and market penetration. Additionally, monitoring the companys cash burn rate and cash reserves is crucial, as the negative Return on Equity (RoE) of -17.21% indicates that Amarin is currently unprofitable. The forward Price-to-Earnings (P/E) ratio of 500.00 suggests high growth expectations, but also implies significant uncertainty.
From a commercial perspective, Amarins reliance on a single product, VASCEPA, poses a risk. However, the companys collaboration with Mochida Pharmaceutical Co., Ltd. and its efforts to expand into new markets may help mitigate this risk. To assess the companys potential for long-term success, its essential to monitor its pipeline development, regulatory approvals, and competitive landscape. Key metrics to watch include the companys research and development (R&D) expenses, as a percentage of revenue, and the progress of its ongoing clinical trials.
AMRN Stock Overview
| Market Cap in USD | 310m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1993-04-01 |
AMRN Stock Ratings
| Growth Rating | -16.2% |
| Fundamental | 10.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 6.43% |
| Analyst Rating | 2.33 of 5 |
AMRN Dividends
Currently no dividends paidAMRN Growth Ratios
| Growth Correlation 3m | -35.1% |
| Growth Correlation 12m | 45.5% |
| Growth Correlation 5y | -94.3% |
| CAGR 5y | -13.53% |
| CAGR/Max DD 3y | -0.17 |
| CAGR/Mean DD 3y | -0.22 |
| Sharpe Ratio 12m | -0.46 |
| Alpha | 0.27 |
| Beta | 0.492 |
| Volatility | 54.97% |
| Current Volume | 38.6k |
| Average Volume 20d | 46.3k |
| Stop Loss | 14.3 (-4.2%) |
| Signal | 0.14 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-103.6m TTM) > 0 and > 6% of Revenue (6% = 11.6m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -5.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 217.8% (prev 177.5%; Δ 40.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -11.5m > Net Income -103.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (414.5m) change vs 12m ago 0.75% (target <= -2.0% for YES) |
| Gross Margin 42.54% (prev 55.95%; Δ -13.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 26.29% (prev 33.19%; Δ -6.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.4k (EBITDA TTM -77.6m / Interest Expense TTM 7000 ) >= 6 (WARN >= 3) |
Altman Z'' -11.98
| (A) 0.63 = (Total Current Assets 606.8m - Total Current Liabilities 185.9m) / Total Assets 670.1m |
| (B) -2.53 = Retained Earnings (Balance) -1.70b / Total Assets 670.1m |
| warn (B) unusual magnitude: -2.53 — check mapping/units |
| (C) -0.11 = EBIT TTM -79.8m / Avg Total Assets 735.0m |
| (D) -6.77 = Book Value of Equity -1.39b / Total Liabilities 205.2m |
| Total Rating: -11.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 10.58
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -14.32% = -5.0 |
| 3. FCF Margin -16.05% = -6.02 |
| 4. Debt/Equity 0.44 = 2.40 |
| 5. Debt/Ebitda -2.64 = -2.50 |
| 6. ROIC - WACC (= -21.04)% = -12.50 |
| 7. RoE -21.18% = -2.50 |
| 8. Rev. Trend -88.87% = -6.67 |
| 9. EPS Trend -42.73% = -2.14 |
What is the price of AMRN shares?
Over the past week, the price has changed by -1.91%, over one month by -7.67%, over three months by +7.56% and over the past year by +26.35%.
Is Amarin a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMRN is around 12.79 USD . This means that AMRN is currently overvalued and has a potential downside of -14.33%.
Is AMRN a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the AMRN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11 | -26.3% |
| Analysts Target Price | 11 | -26.3% |
| ValueRay Target Price | 13.8 | -7.8% |
Last update: 2025-09-12 04:31
AMRN Fundamental Data Overview
CCE Cash And Equivalents = 298.7m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 500.0
P/S = 1.4138
P/B = 0.6671
P/EG = -1.74
Beta = 0.776
Revenue TTM = 193.2m USD
EBIT TTM = -79.8m USD
EBITDA TTM = -77.6m USD
Long Term Debt = 19.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 185.9m USD (from totalCurrentLiabilities, last quarter)
Debt = 205.2m USD (Calculated: Short Term 185.9m + Long Term 19.3m)
Net Debt = -140.5m USD (from netDebt column, last quarter)
Enterprise Value = 216.6m USD (310.1m + Debt 205.2m - CCE 298.7m)
Interest Coverage Ratio = -11.4k (Ebit TTM -79.8m / Interest Expense TTM 7000 )
FCF Yield = -14.32% (FCF TTM -31.0m / Enterprise Value 216.6m)
FCF Margin = -16.05% (FCF TTM -31.0m / Revenue TTM 193.2m)
Net Margin = -53.61% (Net Income TTM -103.6m / Revenue TTM 193.2m)
Gross Margin = 42.54% ((Revenue TTM 193.2m - Cost of Revenue TTM 111.0m) / Revenue TTM)
Tobins Q-Ratio = -0.16 (set to none) (Enterprise Value 216.6m / Book Value Of Equity -1.39b)
Interest Expense / Debt = 0.00% (Interest Expense 7000 / Debt 205.2m)
Taxrate = 21.0% (US default)
NOPAT = -79.8m (EBIT -79.8m, no tax applied on loss)
Current Ratio = 3.26 (Total Current Assets 606.8m / Total Current Liabilities 185.9m)
Debt / Equity = 0.44 (Debt 205.2m / last Quarter total Stockholder Equity 464.9m)
Debt / EBITDA = -2.64 (Net Debt -140.5m / EBITDA -77.6m)
Debt / FCF = -6.62 (Debt 205.2m / FCF TTM -31.0m)
Total Stockholder Equity = 489.0m (last 4 quarters mean)
RoA = -15.46% (Net Income -103.6m, Total Assets 670.1m )
RoE = -21.18% (Net Income TTM -103.6m / Total Stockholder Equity 489.0m)
RoCE = -15.71% (Ebit -79.8m / (Equity 489.0m + L.T.Debt 19.3m))
RoIC = -16.33% (NOPAT -79.8m / Invested Capital 489.0m)
WACC = 4.71% (E(310.1m)/V(515.3m) * Re(7.83%)) + (D(205.2m)/V(515.3m) * Rd(0.00%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 57.58 | Cagr: 0.22%
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -31.0m)
EPS Correlation: -42.73 | EPS CAGR: -1.88% | SUE: 4.0 | # QB: 1
Revenue Correlation: -88.87 | Revenue CAGR: -21.24% | SUE: N/A | # QB: None
Additional Sources for AMRN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle